Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -

Inclusion Criteria: * Age at least 18y * Significant ISR lesion (\>50% by visual estimate) of previously stented de novo coronary artery * Evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia) or ISR with diameter stenosis \> 70% * Written, informed consent * Target lesion(s) located in a native coronary artery within a previously stented lesion with previous stent diameter of ≥ 2.5 mm and ≤ 4.00 mm * Target lesion(s) amenable for percutaneous coronary intervention Exclusion Criteria: * Hypersensitivity to aspirin, clopidogrel, heparin, sirolimus, paclitaxel or radiocontrast media * Systemic sirolimus use within 12 months * Female of childbearing potential * History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia) * Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months * Non-cardiac co-morbid conditions present with life expectancy \<1 year or that may result in protocol non-compliance * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period * ISR of left main coronary artery * Restenosis of two stented bifurcation lesion